Zepp Health Corporation Reports Q2 2026 Financial Results with 6.9% Revenue Growth

Zepp Health Corporation (NYSE: ZEPP) announced its unaudited financial results for the second quarter of 2026, reporting revenue of US$63.5 million, a 6.9% increase year-over-year. The gross margin improved to 37.4%, up 1.2 percentage points from Q2 2025. However, the company recorded a net loss attributable to Zepp of US$11.3 million, compared to a US$7.7 million loss in the same period last year, primarily due to foreign-exchange headwinds and increased investments in R&D, marketing, and brand building. The company also provided Q3 2026 net revenue guidance between US$68.0 million and US$73.0 million.